You are here
ALL Trial Results “Very Positive” for Blinatumomab
Nicola Gökbuget, MD, of Goethe University in Frankfurt, Germany, discusses “very positive” results from trials of the bispecific T-cell engager blinatumomab in treating acute lymphocytic leukemia. Among 116 patients with high levels of minimal residual disease (MRD), 80% were found to be MRD-negative after just one cycle of treatment. Survival results were best if patients were treated in their first remission.